Pfizer advances monthly obesity drug trials; McDonald's tests AI drive-thru; Marvell and Flex join S&P 500.

Pfizer reported positive mid-stage trial results for berobenatide, a potential first GLP-1 obesity therapy with monthly dosing, planning up to 10 Phase 3 trials this year. McDonald's is piloting ArchIQ, an AI-powered drive-thru system, automating 90% of orders in five U.S. locations but facing mixed public reactions. Meanwhile, Marvell Technology and Flex will join the S&P 500 index on June 22, replacing Pool Corporation and Campbell's Company, with shares rising on the announcement.